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Objective: Whether the sequence of pulmonary vein and artery ligation in
pulmonary lobectomy for carcinoma affects intraoperative hematogenous
cancer cell dissemination is not known. We examined whether vessel ligation
sequence affects the presence of circulating cancer cells as reflected by
carcinoembryonic antigen messenger ribonucleic acid. Methods: We assayed for
the transcripts of carcinoembryonic antigen messenger ribonucleic acid by
reverse-transcriptase polymerase chain reaction in peripheral blood taken
before, during, and after operation from 30 patients with non–small-cell lung
cancer who underwent a curative lobectomy and from six patients with
limited-stage small-cell lung cancer who were treated initially with chemother-
apy followed by lobectomy. Each patient was randomly assigned before the
operation to have either pulmonary vein ligation or pulmonary artery ligation
first. Blood taken from 10 patients with interstitial pulmonary fibrosis who
underwent an open lung biopsy and 41 healthy subjects served as a control.
Results: No control samples were positive for transcripts. Sixteen of the
preoperative blood samples from the 30 patients with non–small-cell cancers
were positive. Of these 16, eight samples remained positive even after lobec-
tomy was performed; the remaining eight samples (four in each ligation group)
became negative. Of the 14 initially negative samples (seven in each ligation
group), nine samples became positive during the operation. Such conversion
during the operation was more common with arterial ligation first (six
patients, 85.7%) than with venous ligation first (three patients, 42.9%).
Samples from all six patients with small-cell cancer were positive before the
operation, and five of six samples remained positive after the operation.
Conclusions: Many patients with non–small-cell lung cancer have systemic
disease even when they were thought to have resectable tumors. Ligating the
pulmonary vein before ligating the artery may lessen intraoperative hematog-
enous dissemination. Most small-cell lung cancers represent systemic disease
even when considered resectable. (J Thorac Cardiovasc Surg 1998;116:107-13)
An unresolved question important to surgeons iswhether the manipulation of malignant tumors
during an operation promotes the release of the
tumor cells into the bloodstream, thereby increasing
the incidence of distant metastases. Because of this
concern, some thoracic surgeons insist that, in the
cases of lobectomies for lung carcinoma, the pulmo-
nary vein (PV) should be ligated before the ligation
of the pulmonary artery (PA) because this proce-
dure may prevent tumor cell dissemination into the
bloodstream; conversely, the reverse order may en-
hance tumor cell dissemination during an operation
and promote metastasis formation. However, it is
still controversial whether the order of ligation of
the PV and PA during a resection for lung carci-
noma has any clinical significance.
There is some evidence from animal studies that
indicates that intraoperative manipulation of a tu-
mor can enhance metastasis formation1; however,
whether this is true for human beings is unclear.
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Recently, developments in molecular technology
have permitted the detection of circulating tumor
cells in the peripheral blood.2, 3 Several researchers
have used carcinoembryonic antigen (CEA) as the
target gene because CEA messenger ribonucleic
acid (mRNA) can be detected in almost all epithe-
lial cells, including cancer cells, but not in nonepi-
thelial cells.4, 5 If CEA mRNA is detected in blood
samples, this implies the presence of ectopic epithe-
lial cells.
In this study, we detected the presence of CEA
mRNA in the peripheral blood of patients with
non–small-cell lung cancer (NSCLC) and small-cell
lung cancer (SCLC) during the operation by means
of the reverse-transcriptase polymerase chain reac-
tion (RT-PCR) assay. This RT-PCR amplification
method for CEA mRNA is an efficient means of
detecting circulating cancer cells in the peripheral
blood.6 This study was designed to clarify whether
surgical manipulation indeed promotes the dissem-
ination of tumor cells during an operation for lung
cancer. In addition, we examined whether the se-
quence of ligation of vessels (PV and PA) during
lobectomy for lung cancer has any influence on
tumor cell dissemination into the bloodstream.
Patients and methods
Patients. We studied 30 patients with NSCLC, 21 men
and 9 women, aged 52 to 72 years (mean, 63 years), who
underwent a curative lobectomy with mediastinal lymph
node dissection (R2) at the Department of Surgery II,
Kumamoto University Hospital, and at the Department of
Thoracic Surgery, Kumamoto Chuo Hospital, during the
11-month period from December 1996 to October 1997.
In addition, we studied six patients with limited-stage
SCLC, all men, aged 60 to 76 years (mean, 67 years), who
were treated initially with chemotherapy followed by an
operation. Each patient with SCLC received two or three
cycles of chemotherapy, consisting of doxorubicin (Adria-
mycin) 40 mg/m2 per day on days 1 and 7, cisplatin 50
mg/m2 per day on days 2 and 8, and etoposide 100 mg/m2
per day on days 4 to 6. After two or three cycles when a
greater than 50% reduction in the tumor was achieved,
the patients underwent a surgical resection (lobectomy) of
the primary tumor for better control of the primary site.
Although the patients with SCLC included in this study do
not meet the criteria in which surgical resection is gener-
ally acknowledged to be appropriate in Western countries,
this mode of surgery was still widespread in Japan, and we
performed it at patient request. Informed consent was
obtained from each patient, and the study was approved
by the ethics committees of our institutes.
The postoperative pathologic TNM stage (pTNM) was
determined according to the classification of the Interna-
tional Union Against Cancer.7 The histologic classifica-
tion of the resected tumor specimens was based on the
World Health Organization Histologic Typing of Lung
Tumors.8 When SCLC was suspected, immunostaining
with chromogranin A was performed to confirm the
diagnosis. To rule out potential mesotheliomas, hyaluron-
idase digestion followed by alcian blue staining was per-
formed.
Blood samples. All procedures were performed after
the patient had been given a general anesthetic and with
the use of single-lung ventilation through a double-lumen
endotracheal tube (Broncho-Cath; Mallinckrodt Medical
Inc., St. Louis, Mo.). Patients were placed in the lateral
decubitus position with arms extended on an arm rest. The
operations performed for the 30 patients with NSCLC
were a right upper lobectomy in six patients, a right
middle lobectomy in one patient, right lower lobectomy in
four patients, left upper lobectomy in 15 patients, and left
lower lobectomy in four patients. The operations per-
formed for the six patients with SCLC were a right upper
lobectomy in two patients and a left upper lobectomy in
four patients. All patients were randomly assigned before
the operation to one of two surgical procedure groups
according to the order of vessel ligation, PV-first group
(PV ligation preceded the PA ligation) and PA-first group
(PA ligation preceded the PV ligation). All the surgical
procedures were uniformly and successfully performed by
the two same authors (J.Y. and N.F.). Pulmonary vessel
mobilization and ligation were the first manuevers after
entry into the pleural space. Mediastinal lymph node
dissection was performed after the completion of lobec-
tomy. All the patients had uneventful postoperative re-
coveries.
During the operation, a polyethylene catheter (Becton
Dickinson, Sandy, Utah) was inserted into the radial
artery of the contralateral arm (opposite the lobectomy
side) for monitoring the heart rate and blood pressure.
Blood samples were taken from this line just before the
operation, 5 minutes after the ligation of the PV in the
PV-first group (or the PA in the PA-first group), followed
by sampling 5 minutes after the ligation of the PA in the
PV-first group (or the PV in the PA-first group), and
finally 5 minutes after the completion of the lobectomy.
These four sampling points in each patient were defined
as points I, II, III, and IV, respectively.
As a control, blood samples were taken from the radial
artery before the operation and again 5 minutes after the
lung resection in 10 patients with interstitial pulmonary
fibrosis who underwent an open lung biopsy for the
histologic diagnosis. The diagnoses were usual interstitial
pneumonia in seven patients and bronchiolitis obliterans
organizing pneumonia in three patients. In addition,
blood samples were obtained from the antecubital vein of
32 healthy volunteers, 23 men and 9 women aged between
24 and 65 years (mean, 50 years), and from the radial
artery of 9 healthy volunteers, 7 men and 2 women aged
between 24 and 42 years (mean, 31 years).
RNA extraction. A tube containing a 5 ml blood sam-
ple, 10 ml of 3% dextran, and 0.9% sodium chloride
solution was shaken gently by hand and incubated for 20
minutes at room temperature. The supernatant was cen-
trifuged at 3000 rpm, and the nucleated cells were recov-
ered. After being washed with phosphate-buffered saline
solution, the cells were pelleted and then lysed in Trizol
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reagent (GIBCO BRL, Eggenstein, Germany). Total RNA
was extracted from the cell pellet by the acid guanidium
thiocyanate-phenol-chloroform extraction procedure.9 After
preparation, RNA was resuspended in 10 ml diethylpyrocar-
bonate-treated water and stored at –80° C.
RT-PCR for CEA mRNA. The complementary deoxyri-
bonucleic acid (cDNA) was synthesized from 2.0 mg of
total RNA in a total volume of 20 ml containing 2 ml of
10 3 PCR buffer, 2 ml of 25 mol/L MgCl2, 10 nmol/L of
deoxyribonucleoside trisphosphate mix, 2 ml of 0.1 mol/L
dithiothreitol, 0.5 mg of oligo primer, and 200 units of
SuperScriptII RT (all reagents were obtained from
GIBCO BRL). The reaction mix was incubated for 50
minutes at 42° C, 15 minutes at 70° C, and chilled on ice.
To inactivate the reverse transcriptase, 200 units of Esch-
erichia coli RNaseH (GIBCO BRL) was incubated for 60
minutes at 37° C.
To monitor cDNA synthesis, 2 ml of the mixture was
subjected to a RT-PCR for b-actin. Twenty-five ml of the
PCR reaction mix contained 2 ml of cDNA from the
previous RT reaction, 2.5 ml of 10 3 PCR buffer, 1.17
mmol MgCl2, 2.5 ml of dimethylsulfoxide, 37.5 nmol/L
deoxyribonucleoside trisphosphate mix, 25 pmol/L of
sense and anti-sense primer (each), and 0.5 units of Taq
DNA polymerase (GIBCO BRL). Amplification was car-
ried out in a thermocycler (Thermoblock Uno; Biometra,
Goettingen, Germany) with an initial denaturation step of
95° C for 5 minutes followed by 35 cycles of denaturation
at 95° C for 30 seconds annealing at 55° C for 1 minute
and extension at 72° C for 1 minute. The reaction was
terminated by a final extension step at 72° C for 5 minutes.
The RT-PCR product migrated as a 1100 base-pair (bp)
fragment in a 2% agarose gel electrophoresis. The b-actin
primer sequences were as follows: 59-ATGGATGAT-
Table I. CEA mRNA expression during operation for NSCLC in terms of the operative procedure
Patient no./age
(yr)/sex
Histologic
type
Operation
performed
pTNM classification RT-PCR for CEA mRNA point
T N Stage I II III IV
PV-first group*
1/59/M Adeno LUL 1 0 I 1 1 1 1
2/55/M Adeno RLL 2 0 I 1 1 1 1
3/72/M Squamous LUL 2 2 IIIA 1 1 1 1
4/67/F Adeno RUL 2 2 IIIA 1 1 1 1
5/59/M Squamous LUL 1 0 I 1 – – –
6/63/F Adeno RUL 2 0 I 1 – – –
7/62/M Large RUL 2 2 IIIA 1 – – –
8/70/M Adeno LUL 1 0 I 1 – – –
9/61/M Adeno LLL 2 0 I – 1 1 –
10/65/M Squamous LUL 1 0 I – 1 1 –
11/54/F Squamous RUL 2 0 I – 1 1 –
12/64/M Adeno LUL 1 0 I – – – –
13/69/M Adeno RLL 2 0 I – – – –
14/69/F Squamous LUL 2 0 I – – – –
15/58/M Adeno LLL 2 0 I – – – –
PA-first group†
16/63/M Adeno RML 2 0 I 1 1 1 1
17/67/M Adeno LLL 2 2 IIIA 1 1 1 1
18/68/F Adeno LUL 2 0 I 1 1 1 1
19/71/M Squamous RUL 1 0 I 1 1 1 1
20/64/F Large LUL 2 2 IIIA 1 1 – –
21/52/M Adeno LUL 1 0 I 1 1 – –
22/56/M Squamous RLL 2 0 I 1 1 – –
23/60/M Squamous LUL 2 0 I 1 1 – –
24/70/F Adeno RLL 1 0 I – 1 1 –
25/63/M Adeno LUL 1 0 I – 1 1 –
26/59/F Adeno LUL 2 0 I – 1 1 –
27/72/M Adeno LLL 1 0 I – 1 1 –
28/62/M Adeno RUL 2 0 I – 1 1 –
29/68/M Adeno LUL 2 0 I – 1 1 –
30/53/F Squamous LUL 2 0 I – – – –
Plus signs (1) indicate positive results by RT-PCR for CEA mRNA. Minus signs (2) indicate negative results by RT-PCR for CEA mRNA. Points I, II, III,
and IV represent four blood sampling points for each patient. pTNM, Pathologic TNM; Adeno, adenocarcinoma; LUL, left upper lobectomy; RLL, right lower
lobectomy; Squamous, squamous cell carcinoma; RUL, right upper lobectomy; Large, large-cell carcinoma; LLL, left lower lobectomy; RML, right middle
lobectomy.
*Patients whose PV was ligated first followed by PA ligation.
†Patients whose PA was ligated first followed by PV ligation.
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GATATCGCCGCG-39 and 59-CTAGAAGCATTTGC-
GGTGGACGATGGAGGGGCC-39.
The first PCR amplification was performed with prim-
ers CEA-A and CEA-B, followed by a second PCR
amplification with primers CEA-C and CEA-B. The CEA
primer sequences were: CEA-A, 59-TCTGGAACTTCTC-
CTGGTCTCTCAGCTGG-39;CEA-B,59-TGTAGCTGT-
TGCAAATGCTTTAAGGAAGAAGC-39; and CEA-C,
59-GGGCCACTGTCGGCATCATGATTGG-39.5, 10 For
the first PCR amplification, 1 ml of the cDNA synthesis
mix was used in a final volume of 25 ml. The reaction mix
contained all the components as stated for the b-actin
PCR except that the b-actin primers that were replaced by
CEA-A and CEA-B (25 pmol/L each). The amplification
conditions included denaturation at 95° C for 30 seconds,
annealing at 63° C for 1 minute, and extension at 72° C for
1 minute for 30 cycles by a final extension step at 72° C for
5 minutes. The second nested PCR amplification was
performed in the same way using 2 ml of the first PCR
reaction mix and the primers CEA-C and CEA-B. The
amplification conditions were: denaturation at 95° C for 30
seconds, annealing at 60° C for 1 minute, and extension at
72° C for 1 minute for 30 cycles. The external (first) CEA
RT-PCR resulted in a 160-bp fragment, and the internal
(second) PCR amplification yielded a 131-bp product.
As a positive control, we used 2.0 ng of total RNA from
a NSCLC line EBC-1 (Japanese Research Resources
Bank, Tokyo, Japan). The absence of contamination was
routinely checked by RT-PCR amplification of control
negative samples, in which the RNA was replaced with
sterile water. All RT-PCR products were separated by
electrophoresis in a 3% agarose gel in Tris-borate-ethyl-
ene diamine tetraacetic acid (TBE) buffer and visualized
by ethidium bromide staining. The molecular weights
were determined with a DNA molecular weight marker
(Boehringer Mannheim, Mannheim, Germany).
Results
CEA mRNA expression in blood in NSCLC.
None of the preoperative and intraoperative blood
samples obtained from 10 patients with interstitial
pulmonary fibrosis and none of the 41 control
peripheral blood samples obtained from healthy
volunteers were positive for CEA mRNA by RT-
PCR. Table I shows the results of RT-PCR for CEA
mRNA and the clinical characteristics of all the
patients with NSCLC included in this study. Immu-
nohistochemical staining for CEA revealed that
intense CEA staining was uniformly observed in
tumor cells in all 30 NSCLC specimens (data not
shown). There were five patterns of CEA mRNA
expression by RT-PCR in the blood samples sequen-
tially obtained during the operation in the 30 pa-
tients with NSCLC at sampling points I, II, III, and
Fig. 1. Five patterns of CEA mRNA expression by RT-
PCR in blood samples sequentially obtained during oper-
ations for patients with NSCLC. Points I, II, III, and IV
represent the four blood sampling points in each patient
as described in the Patients and methods section. Lanes M,
P, and N contain the molecular weight marker, positive
control, and negative control, respectively. Lanes I
through IV contain the four sampling points as described.
Fig. 2. Two patterns of CEA mRNA expression by RT-
PCR in blood samples sequentially obtained during the
operations for patients with SCLC. Points I, II, III, and IV
represent the four blood sampling points in each patient
as described in the Patients and methods section. Lanes M,
P, and N contain the molecular weight marker, positive
control, and negative control, respectively. Lanes I
through IV contain the four sampling points as described.
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IV. A representative case of each pattern of CEA
mRNA expression by RT-PCR is shown in Fig. 1.
No significant association was found between
CEA mRNA expression by RT-PCR and age, sex,
histologic type, and operation performed. When
CEA mRNA expression by RT-PCR was compared
with respect to TNM stage, the preoperative blood
samples (point I) of all five patients with stage IIIA
NSCLC were positive: three patient samples were
(1)(1)(1)(1), one patient’s samples were
(1)(1)(–)(–), and one patient’s status was (1)(–)
(–)(–) at sampling points I, II, III and IV, respec-
tively.
The CEA mRNA expression in the peripheral
blood samples during surgery for the 30 patients
with NSCLC in terms of the operative procedure is
summarized in Table II. The preoperative blood
samples from 16 of 30 patients were positive (point
I). Of these 16 patients, the samples from eight
patients (four patients each in the PV-first group
and the PA-first group) were positive for CEA
mRNA at all sampling points, even after the com-
pletion of lobectomy, that is (1)(1)(1)(1). In
addition, peripheral blood samples obtained 1 to 2
days after the operations were positive in these eight
patients (data not shown). The most striking differ-
ence in CEA mRNA expression between the PV-
first group and the PA-first group is that there were
four patients in the PV-first group whose samples
were (1)(–)(–)(–) at the four sampling points, re-
spectively, whereas none of the patients in the
PA-first group had this pattern. In addition, there
were four patients in the PA-first group but none in
the PV-first group whose pattern of CEA mRNA
expression was (1)(1)(–)(–) at the four sampling
points. Furthermore, there was a higher incidence of
patients with a pattern of (–)(1)(1)(–) in the
PA-first group (66.7%) than in the PV-first group
(33.3%), and there was a higher incidence of pa-
tients whose samples were consistently negative,
(–)(–)(–)(–), in the PV-first group (80.0%) than in
the PA-first group (20.0%).
CEA mRNA expression in blood in SCLC. Fig. 2
and Table III show the results of the RT-PCR
amplification for CEA mRNA and the clinical char-
acteristics of the six patients with SCLC included in
this study. The preoperative blood samples from
these patients were positive. Of these six patients
with SCLC, five had samples that were consistently
positive throughout the sampling period, even after
the removal of the tumor, that is, (1)(1)(1)(1).
Only one patient with SCLC had a sample negative
for CEA mRNA by RT-PCR after the completion
of the lobectomy, that is, (1)(1)(1)(–).
Discussion
A method to detect small numbers of tumor cells
in the blood may permit the evaluation of their role
in the disease process. Morphologic techniques, flow
cytometry, conventional cytogenetics, and immuno-
cytochemistry have been used to detect circulating
tumor cells.2 However, these techniques are rela-
tively insensitive and dependent on the availability
of antibodies to tumor-associated cell-surface anti-
gens, which may yield false-positive results if the
antibodies cross-react with normal antigens or tu-
mor antigens are presented on host immune
cells.2, 11 The advent of the PCR has permitted the
detection of one malignant cell up to 107 normal
cells by amplification of tumor-specific sequenc-
es.2, 3, 12 Recently, Gerhard and associates5 devel-
oped a sensitive RT-PCR assay for the specific
detection of CEA-expressing tumor cells in the bone
marrow, and Mori and associates6 have demon-
strated that RT-PCR amplification of CEA mRNA
is an efficient means of detecting circulating cancer
cells in the peripheral blood.
The detachment of cancer cells from the primary
tumor is one of the early sequential events in the
metastatic cascade. Therefore surgeons always
worry that the manual manipulation of a tumor
during an operation might enhance the shedding of
cancer cells into the bloodstream, resulting in an
increase in the incidence of distant metastases. One
surgical technique that might prevent such shedding
is to ligate the efferent vessels first. In lung carci-
noma operations, ligating the PV before ligating the
PA has been postulated as a way to prevent tumor
cell dissemination into the bloodstream. Although
Table II. Summary of CEA mRNA expression
during operation for NSCLC
RT-PCR for
CEA mRNA
point No. of patients
in PV-first
group (%)
No. of patients
in PA-first
group (%)
Total
(%)I II III IV
1 1 1 1 4 (50.0) 4 (50.0) 8 (100)
1 1 – – 0 (0.0) 4 (100.0) 4 (100)
1 – – – 4 (100.0) 0 (0.0) 4 (100)
– 1 1 – 3 (33.3) 6 (66.7) 9 (100)
– – – – 4 (80.0) 1 (20.0) 5 (100)
Total 15 15 30
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there has been considerable debate over this recom-
mendation, it has not been rigorously tested.
In the present study, to examine whether the
order of vessel ligation during an operation for lung
carcinoma has any influence on the presence of
tumor cells in the circulation, we assayed by RT-
PCR for the presence of CEA mRNA in the periph-
eral blood of patients undergoing operations for
lung carcinoma. Surprisingly, CEA mRNA was de-
tected in the peripheral blood samples obtained
before the operation in 16 of 30 patients (53.3%)
with resectable NSCLC. Another unexpected find-
ing in this study was the high incidence (8 of 30
patients, 26.7%) of positive CEA mRNA in the
peripheral blood throughout the study period, even
after the completion of the lobectomy, that is,
(1)(1)(1)(1), at all four time points. Although the
technique does not allow for specific identification
of tumor cells and positive finding of CEA mRNA
merely indicates the presence of epithelial cells, our
results suggest that a considerable proportion of
patients who appear to have resectable NSCLC
might be better regarded as having systemic disease.
In this study, we performed single-point blood sam-
pling for patients before operation. However, cancer
cells may be intermittently shedding into the blood-
stream.13
Thus sampling errors may have occurred in that
patients who had negative blood samples when the
initial blood was drawn might have circulating tumor
cells intermittently at another time or under other
circumstances.
With respect to the order of vessel ligation
during surgery for NSCLC, our results seem to
support the opinion that the PV should be ligated
first, before the ligation of the PA. Both in the
PV-first group and the PA-first group, the blood
samples from eight patients in each group were
positive for CEA mRNA before surgery. Subse-
quently, the samples from four patients in each
group turned negative just after the ligation of the
PV, that is, (1)(–)(–)(–) in the PV-first group and
(1)(1)(–)(–) in the PA-first group. These results
suggest that the ligation of the PV may partly
prevent the shedding of cancer cells into the
bloodstream. Furthermore, in the PV-first group,
blood samples from three of seven patients
(42.9%) that were negative for CEA mRNA be-
fore surgery turned positive during surgery, that
is, (–)(1)(1)(–). The incidence of this change was
higher in the PA-first group (six of seven patients,
85.7%) than in the PV-first group.
The relationship between circulating tumor cells
and the development of metastatic disease is not
fully understood, and the presence of tumor cells in
the blood does not necessarily indicate the subse-
quent risk of clinical systemic disease. It is generally
believed that very few of tumor cells that shed into
the bloodstream succeed in establishing secondary
tumors.14 Thus patients who have persistently posi-
tive blood samples after lobectomy may be those at
risk for systemic relapse. However, our findings
should alert surgeons to the possible danger of
tumor cell dissemination during an operation and
suggest that the PV should be ligated first, before
the ligation of the PA, in patients undergoing a
lobectomy for NSCLC. Future follow-up studies in a
larger cohort of patients with NSCLC should be
done to examine whether the patients with positive
CEA mRNA might have more metastases, shorter
survivals, or shorter disease-free intervals than those
who did not have positive results.
Table III. CEA mRNA expression during operation for SCLC in terms of the operative procedure
Patient no/
age (yr)
Histologic
type
Operation
performed
pTNM classification RT-PCR for CEA mRNA point
T N Stage I II III IV
PV-first group*
31/60 SCLC LUL 2 0 I 1 1 1 1
32/67 SCLC RUL 2 2 IIIA 1 1 1 1
33/76 SCLC LUL 1 0 I 1 1 1 –
PA-first group†
34/62 SCLC RUL 1 0 I 1 1 1 1
35/65 SCLC LUL 2 0 I 1 1 1 1
36/69 SCLC LUL 3 0 IIIA 1 1 1 1
All patients were men. Plus signs (1) indicate positive results by RT-PCR for CEA mRNA. Minus signs (2) indicate negative results by RT-PCR for CEA
mRNA. Points I, II, III, and IV represent four blood sampling points for each patient. pTNM, Pathologic TNM; LUL, left upper lobectomy; RUL, right upper
lobectomy.
*Patients whose PV was ligated first followed by PA ligation.
†Patients whose PA was ligated first followed by PV ligation.
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Our study also demonstrated that most patients
with SCLC had blood samples that were positive by
RT-PCR for CEA mRNA before the operation
despite initial chemotherapy; samples remained
positive even after removal of the primary tumor,
that is, (1)(1)(1)(1). These results suggest that
patients with SCLC, even if they have limited-stage
disease, are likely to have systemic disease, and that
a local treatment modality, such as surgical resec-
tion, is likely to have little impact on their prognosis.
In conclusion, the molecular detection of CEA
mRNA in the peripheral blood of patients with lung
carcinoma suggests that (1) many patients with
resectable NSCLC are likely to have systemic dis-
ease; (2) surgical manipulation can promote the
release of tumor cells into the bloodstream, but the
ligation of the PV before the ligation of the PA may
partly prevent such release during surgery; and (3)
most patients with SCLC are likely to have systemic
disease.
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